Levetiracetam G.L. (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilizes neuronal membranes and reduces excessive neuronal firing, thereby decreasing the likelihood of seizure initiation and spread.

The specific dose of Levetiracetam G.L. is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Healthcare professionals tailor the regimen to achieve optimal seizure control while minimizing side effects.

Safety data for levetiracetam in pregnancy and lactation are limited. Clinicians must weigh potential benefits against unknown risks, and the decision should be individualized. Women who are pregnant or nursing should discuss treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Levetiracetam has a unique mechanism targeting SV2A, offering broad-spectrum seizure control with relatively few drug‑enzyme interactions. Compared with older agents such as carbamazepine or phenytoin, it often requires less therapeutic drug monitoring and may have a more favorable side‑effect profile, though individual response varies.

Levetiracetam G.L. should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability and sterility.

Levetiracetam G.L. is given by intravenous infusion. The rate and duration of infusion are determined by the prescriber, typically based on the patient’s clinical condition and the recommended concentration for safe administration.

Serious risks include severe allergic reactions (anaphylaxis), mood disorders such as depression or suicidal thoughts, and rare hematologic abnormalities. Patients should be monitored for any signs of these conditions, and treatment should be discontinued if severe reactions occur.

Levetiracetam G.L. is contraindicated in patients with known hypersensitivity to levetiracetam or any component of the formulation. Caution is also advised for individuals with severe renal impairment, as dose adjustments may be required.